Skip to content

    3B Blackbio

    532067
    Healthcare·21 Feb 2026
    Management Summary

    3B Blackbio reported strong consolidated revenue growth for the nine months ended December 31, 2025, driven by the Coris acquisition. The company provided guidance for double-digit revenue and export growth for FY26, while focusing on new product development, regulatory approvals (US FDA, IVDR), and strategic M&A to expand its diagnostic portfolio and market reach, particularly in the US and Europe.

    Highlights

    7

    • Consolidated revenue for 9M FY26 (with Coris) was INR 99.06 crores, up 52.87% YoY from INR 64.80 crores (without Coris) in 9M FY25.

    • 3B Blackbio's standalone growth was 11.8% YoY, or over 20% when excluding seasonal spikes.

    • Overall revenue growth guidance for FY26 is 10-15%, with export growth projected at 15-20%.

    • Coris contributed INR 24 crores to Q3 FY26 revenue, including INR 8.8 crores from a one-off HAT contract.

    • Coris is targeted to become EBITDA positive at 2-3% of revenue in FY27.

    • US FDA approval for Coris is anticipated in 1-1.5 years, with full market penetration expected in 3-4 years.

    • IVDR certification for Europe is expected within 6-9 months, crucial for continued market access.

    What Changed2

    vs Q4 FY26

    Guidance items11 → 7 (-4)Risks discussed6 → 3 (-3)
    Key financials

    Metrics

    4

    Periods

    3

    Q3 FY26

    2
    • Coris Revenue
      ₹24 Cr
    • HAT Contract Revenue
      ₹8.8 Cr

    9M FY25, without Coris

    1
    • Revenue
      ₹64.8 Cr

    9M FY26, with Coris

    1
    • Revenue
      ₹99.06 Cr
      YoY+52.9%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    M&A

    Coris (Belgium)

    acquisition · integrated

    M&A

    New Acquisitions

    acquisition · announced · Consideration ₹NaN (undisclosed)

    Liquidity

    Cash ₹190 crores

    Cash position post Coris deal is approximately INR 190 crores.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Overall Revenue Growth
    10-15%
    		High
    Revenue
    Export Revenue Growth
    15-20%
    		High
    Profitability
    Coris EBITDA Margin
    2-3% positive
    		High
    Regulatory
    Coris US FDA Approval
    1-1.5 years
    		Medium
    Regulatory
    IVDR Certification
    6-9 months
    		High
    Product Contribution
    PCR Kit Contribution to Coris Sales
    2-5%
    		Medium
    Listing
    NSE Listing Application
    Post March audited results
    		High

    Coris EBITDA Turnaround

    FY27
    CurrentEBITDA loss of $325k (12 months)
    TargetEBITDA positive (2-3% of revenue)

    Why it matters

    Verifying Coris's profitability turnaround is crucial for the overall consolidated margin improvement and M&A success.

    For next year, we are trying that we are EBITDA positive, maybe 2% or 3% of the revenue.

    How to verify

    key_financials.metrics[label='Coris EBITDA Margin']

    Risks & concerns

    3
    RiskSeverity

    Increased Competition and Margin Pressure

    High margins in molecular diagnostics attract new players, leading to increased competition and potential pressure on pricing and margins, especially for high-volume products. — Both acknowledged

    medium

    Seasonal Fluctuations in Domestic Sales

    Domestic growth can be significantly impacted by seasonal spikes (e.g., Dengue/Flu), making quarter-on-quarter comparisons less reliable and potentially masking underlying growth. — Management acknowledged

    low

    Lengthy Regulatory Approval Processes

    Regulatory approvals like US FDA (1-2 years) and IVDR (6-9 months) are time-consuming, potentially delaying market entry and full commercialization of new products or markets. — Management acknowledged

    medium

    Q&A highlights

    8

    “Any industry which has a high margin, it will have competition. If you just see mobile industry where it was and where it is today. So new players keep coming. I can't ask them why are you coming. It's a very simple thing you know. When the margins are literally low, then probably competition might not come.”

    Management directly addressed the increasing competition, linking it to the high-margin nature of the molecular diagnostics business and the entry of players from other diagnostic segments.

    asked by Ganesh

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance and Growth Drivers

    3B Blackbio Dx Ltd. reported a consolidated revenue of INR 99.06 crores for the nine months ended December 31, 2025, marking a substantial 52.87% year-on-year growth compared to INR 64.80 crores in the prior year (excluding Coris). The standalone 3B Blackbio business grew by 11.8% year-on-year, with an underlying growth exceeding 20% when adjusted for the seasonal Dengue/Flu spike in the previous year. The company projects an overall revenue growth of 10-15% for FY26, with exports expected to grow at a higher rate of 15-20%.

    02

    Coris Acquisition and Integration Strategy

    The recent acquisition of Belgium-based Coris contributed INR 24 crores to the Q3 FY26 revenue, which included INR 8.8 crores from a one-off📎 HAT contract. Coris, specializing in lateral flow and AMR products, recorded an EBITDA loss of $325k over the past 12 months but is targeted to achieve EBITDA positivity at 2-3% of revenue in FY27. The integration strategy is gradual, prioritizing Coris's standalone growth and US market focus, with PCR kit contributions to Coris's sales expected to be 2-5% next year.

    03

    Regulatory Approvals and Market Expansion

    The company is aggressively pursuing regulatory approvals to unlock new markets. US FDA registration for Coris's products is underway, with approval anticipated in 1-1.5 years and full market penetration in 3-4 years, which is deemed crucial for future growth and to offset the eventual sunset of the HAT contract. Additionally, IVDR certification for the European market is expected within 6-9 months, a critical step to ensure continued commercial sales of their products in Europe.

    04

    Product Development and R&D Focus

    3B Blackbio is investing significantly in R&D to expand its product portfolio. Key developments include a sample-to-answer machine (expected next quarter via an OEM model), automated extraction systems, and highly multiplexed kits for respiratory and AMR panels. The company is also developing dPCR and Coris NGS products, primarily to maintain technological relevance and future-proof against potential PCR obsolescence, rather than as immediate profit drivers due to low NGS margins and high competition.

    05

    Competition and Market Dynamics

    Management acknowledges that the high-margin nature of molecular diagnostics attracts increasing competition, which could lead to margin pressure and impact price realization, especially for high-volume products. The total addressable market for their reagent business in India is estimated at INR 400-500 crores. The company emphasizes customer stickiness through a wide product range in infectious and oncology segments, coupled with strong support and service.

    06

    Capital Allocation and Future Growth Initiatives

    Post the Coris acquisition, the company maintains a cash position of approximately INR 190 crores. They are actively seeking new acquisition opportunities, with a target to acquire companies worth INR 130-140 crores, while reserving INR 50 crores for such endeavors. The company also plans to apply for NSE listing post the audited results for March, having met the necessary paid-up capital and net worth requirements.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.